Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Published:2021-09 Issue: Volume:159 Page:128-134
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yoh Kiyotaka,Matsumoto Shingo,Furuya Naoki,Nishino Kazumi,Miyamoto Shingo,Oizumi Satoshi,Okamoto Norio,Itani Hidetoshi,Kuyama Shoichi,Nakamura Atsushi,Nishi Koichi,Fukuda Ikue,Tsuta Koji,Hayashi Yuichiro,Motoi Noriko,Ishii Genichiro,Goto Koichi

Funder

Merck

Eisai

EMD Serono

Kyowa Hakko Kirin

AbbVie

Astellas Pharma

Meso Scale Diagnostics

NEC Corporation

Bayer

Covidien

Pfizer

AstraZeneca

Amgen

Bristol-Myers Squibb

Chugai Pharmaceutical

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses;BMC Cancer;2024-04-17

2. Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study;JTO Clinical and Research Reports;2024-03

3. Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer;Clinical Cancer Research;2024-02-01

4. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

5. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non–Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET, or RET Alterations: A Systematic Literature Review;Journal of Immunotherapy;2023-12-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3